1NBIX Stock Overview

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. More details

1NBIX fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	4/6
Past Performance	1/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 69% below our estimate of its fair value

Earnings are forecast to grow 26.46% per year

Analysts in good agreement that stock price will rise by 31.7%

Risk Analysis

Shares are highly illiquid

Large one-off items impacting financial results

Profit margins (12.7%) are lower than last year (18.7%)

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Neurocrine Biosciences, Inc. Competitors

Philogen

BIT:PHIL

€910.5m

Recordati Industria Chimica e Farmaceutica

BIT:REC

€10.6b

Genmab

CPSE:GMAB

DKK 81.9b

BioMarin Pharmaceutical

NasdaqGS:BMRN

US$11.4b

Price History & Performance

Summary of share price highs, lows and changes for Neurocrine Biosciences
Historical stock prices
Current Share Price	US$107.75
52 Week High	US$106.55
52 Week Low	US$106.35
Beta	0.26
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	16.92%

Recent updates

Shareholder Returns

	1NBIX	IT Biotechs	IT Market
7D	2.5%	1.6%	2.9%
1Y	n/a	0.3%	14.1%

Return vs Industry: Insufficient data to determine how 1NBIX performed against the Italian Biotechs industry.

Return vs Market: Insufficient data to determine how 1NBIX performed against the Italian Market.

Price Volatility

Is 1NBIX's price volatile compared to industry and market?
1NBIX volatility
1NBIX Average Weekly Movement	n/a
Biotechs Industry Average Movement	8.4%
Market Average Movement	5.4%
10% most volatile stocks in IT Market	8.8%
10% least volatile stocks in IT Market	3.4%

Stable Share Price: 1NBIX's share price has been volatile over the past 3 months compared to the Italian market.

Volatility Over Time: Insufficient data to determine 1NBIX's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1992	1,800	Kyle Gano	www.neurocrine.com

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy and schizophrenia; NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, and NBI-1065890 for neuropsychiatric and neurological conditions.

Neurocrine Biosciences, Inc. Fundamentals Summary

How do Neurocrine Biosciences's earnings and revenue compare to its market cap?
1NBIX fundamental statistics
Market cap	€10.68b
Earnings (TTM)	€274.27m
Revenue (TTM)	€2.16b

39.2x

P/E Ratio

5.0x

P/S Ratio

Is 1NBIX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1NBIX income statement (TTM)
Revenue	US$2.41b
Cost of Revenue	US$870.60m
Gross Profit	US$1.54b
Other Expenses	US$1.24b
Earnings	US$305.80m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	3.09
Gross Margin	63.91%
Net Profit Margin	12.68%
Debt/Equity Ratio	0%

How did 1NBIX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/16 22:49
End of Day Share Price	2025/05/16 00:00
Earnings	2025/03/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Neurocrine Biosciences, Inc. is covered by 45 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Martha Freitag	Argus Research Company
Brian Skorney	Baird
Ishan Majumdar	Baptista Research

Neurocrine Biosciences BIT:1NBIX Stock Report